Emgality

Active Ingredient(s): Galcanezumab-gnlm
FDA Approved: * September 27, 2018
Pharm Company: * ELI LILLY AND CO
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Emgality Overview

Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[1][2] It is directed against calcitonin-related polypeptides alpha and beta. This drug was developed by Eli Lilly & Co. As of July2017[update].[3] The drug was approved by the US FDA in September 2018, becoming the third marketed CGRP inhibitor for the United States.[4] See also Oth...

Read more Emgality Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Galcanezumab

Recent Emgality Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Galcanezumab-gnlm

Injection: 120mg/ml

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Emgality: (2 results)

Sorted by National Drug Code

0002-1436 Emgality 120 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company
0002-2377 Emgality 120 mg/ml Subcutaneous Injection, Solution by Eli Lilly and Company

Other drugs which contain Galcanezumab-gnlm or a similar ingredient: (1 result)

GALCANEZUMAB